EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
No biomarker	Oral Cancer	No biomarker	Oral Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	afatinib Resistant: A2 - Guideline afatinib Resistant : A2	afatinib Resistant: A2 - Guideline afatinib Resistant : A2
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	neratinib Sensitive: A2 - Guideline neratinib Sensitive : A2	neratinib Sensitive: A2 - Guideline neratinib Sensitive : A2
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib Sensitive: B - Late Trials pyrotinib Sensitive : B	pyrotinib Sensitive: B - Late Trials pyrotinib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
HER-2 exon 20 mutation	Non Small Cell Lung Cancer	HER-2 exon 20 mutation	Non Small Cell Lung Cancer	poziotinib Sensitive: B - Late Trials poziotinib Sensitive : B	poziotinib Sensitive: B - Late Trials poziotinib Sensitive : B
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pyrotinib Sensitive: B - Late Trials trastuzumab + pyrotinib Sensitive : B	trastuzumab + pyrotinib Sensitive: B - Late Trials trastuzumab + pyrotinib Sensitive : B
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	osimertinib + afatinib Sensitive: B - Late Trials osimertinib + afatinib Sensitive : B	osimertinib + afatinib Sensitive: B - Late Trials osimertinib + afatinib Sensitive : B
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + neratinib Sensitive: B - Late Trials trastuzumab + neratinib Sensitive : B	trastuzumab + neratinib Sensitive: B - Late Trials trastuzumab + neratinib Sensitive : B
HER-2 overexpression	Breast Cancer	HER-2 overexpression	Breast Cancer	neratinib Sensitive: B - Late Trials neratinib Sensitive : B	neratinib Sensitive: B - Late Trials neratinib Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	neratinib Resistant: B - Late Trials neratinib Resistant : B	neratinib Resistant: B - Late Trials neratinib Resistant : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR amplification	Squamous Cell Carcinoma of Head and Neck	EGFR amplification	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
ERBB3-L	Squamous Cell Carcinoma of Head and Neck	ERBB3-L	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B

HER4 inhibitor

HER4 inhibitor

Associations(430)

Associations
(430)